Cardiologists Now Have New Resource To Manage The Leading Anticoagulant Drug.

Business Editors & Health/Medical Writers

RALEIGH, N.C.--(BUSINESS WIRE)--Oct. 11, 2002

PharmaNetics Inc (Nasdaq NM: PHAR) - Cardiologists today are being offered a new resource in order to effectively manage the leading anticoagulant drug, enoxaparin with the launch of a new website, www. Enoxtest.com.

The website answers many of the key questions that physicians may have in using the Rapidpoint(R) Coag Enox Test, including its intended use and performance characteristics. Other features of the website include sections for FAQs, a calendar of events, ordering information, company contact information and clinical abstracts and publications.

With this new website, cardiologists can now access detailed information on the ENOX test in order to circumvent the complexity and limited availability of more traditionally used anti-Xa laboratory tests for monitoring enoxaparin. The greatest limitation of the Anti-Xa tests is its inability to generate test results in a timely manner as required in a critical care environment.

The Rapidpoint(R) Coag ENOX Test received FDA clearance at the end of August, 2002 and is used to detect the anticoagulant effects of enoxaparin sodium, a pharmaceutical indicated for prophylaxis of deep vein thrombosis (DVT) and for prophylaxis of ischemic complications of unstable angina and non-Q wave myocardial infarction or heart attack ("UA/NQWMI").

A primary market for enoxaparin has been patients who present at the emergency room with chest pain and are diagnosed with unstable angina. The treatment regiment is to provide an anticoagulant .The preferred anticoagulant, as demonstrated in numerous studies, is enoxaparin because it is easier to administer and provides more predictable results than the historical standard of care, unfractionated heparin. The problem occurs when patients who are initiated on enoxaparin are transferred to the cardiac intervention lab for angioplasty or other revascularization procedures. The cardiologist today has no means to determine the level of anticoagulation the patient has when on enoxaparin. Thus, the patient is often taken off enoxaparin and put on heparin in order to better manage the anticoagulation status.

About PharmaNetics

PharmaNetics, Inc., a leading biotechnology company, coined the term "theranostics," defining an emerging new field of medicine that enables physicians to therapeutically manage coagulation parameters of their patients in the treatment of angina, myocardial infarction (heart attack), stroke, and pulmonary and arterial emboli. The Company's proprietary diagnostic platform generates rapid feedback on blood clot formation and dissolution. It's technology platform is the primary driver of existing collaborations with a number of major pharmaceutical companies, to develop theranostic tests for specific compounds and disease indications being targeted by these corporations. For more information about the Company, please visit PharmaNetics' website at: www.pharmanetics.com

This press release contains forward-looking statements regarding future events and the future performance of PharmaNetics that involve risks and uncertainties, such as risks related to market acceptance, clinical trials and dependence on third-party distributors and collaborative partners that could cause actual results to differ materially from those projected in the forward-looking statements. Information concerning these and other of the factors that could cause actual results to materially differ from those in the forward-looking statements is contained in the Company's SEC filings, including Form 10-K, Form 10-Q and Form 8-K reports.